secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K/A
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001384101-24-000051
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte completes C2i acquisition for up to $95M stock; C2i had $36M loss, $78.6M debt
--------------------------------------------------------------------------------

- Acquisition closed Feb 5, 2024; total consideration up to $95M in Veracyte common stock.
- C2i 2023 revenue $456k, net loss $36.0M, R&D expense $17.9M, operating loss $21.9M.
- C2i had $78.6M in convertible promissory notes, $18.8M cash, $76.1M accumulated deficit as of Dec 31, 2023.
- Veracyte files audited C2i financials and unaudited pro forma combined statements to satisfy SEC requirements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000051/0001384101-24-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000051/vcyt-20240205.htm
  HTML page:      https://secwatch.observer/filing/0001384101-24-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer